ANIX net incomeQ3 2026-$2.61M
ANIX net income was -$2.61M in fiscal Q3 2026 (ended Jul 31, 2026), compared with -$2.26M a year earlier. For the full fiscal 2025 it was -$10.93M, compared with -$12.55M in fiscal 2024.
Anixa Biosciences Inc. (ANIX) financials
For the twelve months ended Jul 31, 2026, Anixa Biosciences Inc. reported -$10.38M of net income.
- Net income, TTM
- -$10.38M
- Cash
- $1.40M
- Market cap
- $110.5M
FY2016FY2024
FY2016FY2025
FY2016FY2020
ANIX revenue and earnings growth
ANIX EPSQ3 2026-$0.08
ANIX diluted EPS was -$0.08 in fiscal Q3 2026 (ended Jul 31, 2026), compared with -$0.07 a year earlier. For the full fiscal 2025 it was -$0.34, compared with -$0.39 in fiscal 2024.
Income statement
| Line item | Oct 31, 2025 | Oct 31, 2024 | Oct 31, 2023 | Oct 31, 2022 | Oct 31, 2021 | Oct 31, 2020 | Oct 31, 2019 | Oct 31, 2018 | Oct 31, 2017 | Oct 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $210.0K | $210.0K | - | $512.0K | - | $250.0K | $1.11M | $362.5K | $300.0K |
| Research and development | $5.07M | $6.40M | $4.77M | $6.70M | $6.19M | $4.38M | $5.47M | $6.81M | $1.60M | $1.56M |
| Selling, general and admin | $6.63M | $7.43M | $6.29M | $7.17M | $7.07M | $5.60M | $5.66M | $6.91M | $4.41M | $2.71M |
| Operating income | -$11.70M | -$13.83M | -$11.01M | -$13.88M | -$13.14M | -$9.98M | -$11.89M | -$14.29M | -$6.08M | -$4.51M |
| Interest expense | - | - | - | - | - | - | - | - | $500.5K | $519.9K |
| Pre-tax income | - | - | - | - | - | - | -$11.82M | -$14.24M | -$5.01M | -$5.02M |
| Net income | -$10.93M | -$12.55M | -$9.81M | -$13.60M | -$12.95M | -$10.02M | -$11.65M | -$14.00M | -$5.01M | -$5.02M |
| EPS, basic | -$0.34 | -$0.39 | -$0.32 | $0.45 | -$0.45 | -$0.45 | -$0.59 | -$0.79 | -$0.58 | -$0.57 |
| EPS, diluted | -$0.34 | -$0.39 | -$0.32 | $0.45 | -$0.45 | -$0.45 | -$0.59 | -$0.79 | -$0.58 | -$0.57 |
| Diluted shares | 32,454 | 31,898 | 30,980 | 30,374 | 28.6M | 22.2M | 19.8M | 17.6M | 12.2M | 8.7M |
Balance sheet
| Line item | Oct 31, 2025 | Oct 31, 2024 | Oct 31, 2023 | Oct 31, 2022 | Oct 31, 2021 | Oct 31, 2020 | Oct 31, 2019 | Oct 31, 2018 | Oct 31, 2017 | Oct 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.24M | $1.27M | $915.0K | $12.36M | $29.13M | $6.42M | $3.49M | $3.06M | $3.34M | $2.49M |
| Short-term investments | $13.93M | $18.65M | $22.93M | $17.33M | $6.60M | $2.64M | $2.35M | $2.00M | $3.50M | $750.0K |
| Receivables | - | $173.0K | $270.0K | $46.0K | - | $2.2K | $66.5K | $307.0K | - | - |
| Current assets | $15.89M | $21.36M | $25.36M | $30.20M | $36.00M | $9.37M | $6.09M | $5.54M | $7.01M | $3.40M |
| Total assets | $16.08M | $21.59M | $25.52M | $30.41M | $36.26M | $9.45M | $6.29M | $6.45M | $8.81M | $5.63M |
| Current liabilities | $1.97M | $2.50M | $2.03M | $2.04M | $1.27M | $1.19M | $1.48M | $1.27M | $889.5K | $468.8K |
| Total liabilities | $2.13M | $2.70M | $2.15M | $2.21M | $1.49M | $1.19M | $1.48M | $1.27M | $889.5K | $4.64M |
| Shareholders' equity | $15.16M | $18.89M | $23.37M | $28.20M | $34.77M | $8.26M | $4.81M | $5.18M | $7.92M | $987.5K |
Cash flow
| Line item | Oct 31, 2025 | Oct 31, 2024 | Oct 31, 2023 | Oct 31, 2022 | Oct 31, 2021 | Oct 31, 2020 | Oct 31, 2019 | Oct 31, 2018 | Oct 31, 2017 | Oct 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.17M | -$7.33M | -$6.21M | -$6.49M | -$4.94M | -$6.18M | -$4.74M | -$4.27M | -$3.80M | -$3.38M |
| Capital expenditures | - | - | - | - | - | $15.8K | $175.5K | $38.4K | $30.2K | $146.5K |
| Free cash flow | - | - | - | - | - | -$6.19M | -$4.92M | -$4.31M | -$3.83M | -$3.53M |
| Investing cash flow | $4.87M | $4.28M | -$5.60M | -$10.73M | -$3.92M | -$305.8K | -$525.5K | $1.46M | -$2.74M | $1.50M |
| Financing cash flow | $2.28M | $3.42M | $366.0K | $452.0K | $31.57M | $9.41M | $5.70M | $2.53M | $7.38M | -$2.7K |
| Share repurchases | - | $6.0K | - | - | - | - | - | - | - | - |
| Stock-based compensation | $3.68M | $4.42M | $4.42M | $6.00M | $7.50M | $3.92M | - | - | - | - |
| Depreciation and amortization | - | - | - | - | - | - | - | $18.4K | $43.2K | $33.3K |
Key ratios
| Line item | Oct 31, 2025 | Oct 31, 2024 | Oct 31, 2023 | Oct 31, 2022 | Oct 31, 2021 | Oct 31, 2020 | Oct 31, 2019 | Oct 31, 2018 | Oct 31, 2017 | Oct 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | 0.0% | - | - | - | - | -77.5% | 206.9% | 20.8% | -96.8% |
| Operating margin | - | -6586.2% | -5243.3% | - | -2565.6% | - | -4756.0% | -1284.4% | -1676.0% | -1503.0% |
| Net margin | - | -5978.1% | -4671.9% | - | -2530.1% | - | -4658.8% | -1258.1% | -1381.8% | -1672.1% |
| Free cash flow margin | - | - | - | - | - | - | -1966.8% | -387.6% | -1055.7% | -1176.1% |
| Return on equity | -72.1% | -66.5% | -42.0% | -48.2% | -37.3% | -121.2% | -242.0% | -270.0% | -63.2% | -508.0% |
| Return on assets | -68.0% | -58.1% | -38.4% | -44.7% | -35.7% | -106.0% | -185.1% | -217.0% | -56.8% | -89.1% |
| Current ratio | 8.08 | 8.54 | 12.50 | 14.83 | 28.35 | 7.88 | 4.11 | 4.38 | 7.89 | 7.25 |
Income statement
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $0 |
| Research and development | $1.33M | $1.26M | $1.10M | $1.14M | $1.05M | $1.32M | $1.55M | $1.48M | $1.93M | $1.65M | $1.35M | $1.61M |
| Selling, general and admin | $1.41M | $1.39M | $1.61M | $1.73M | $1.38M | $1.68M | $1.83M | $1.69M | $1.67M | $1.82M | $2.26M | $1.44M |
| Operating income | -$2.74M | -$2.65M | -$2.72M | -$2.88M | -$2.44M | -$3.00M | -$3.39M | -$3.16M | -$3.59M | -$3.47M | -$3.61M | -$3.05M |
| Net income | -$2.61M | -$2.52M | -$2.56M | -$2.69M | -$2.26M | -$2.79M | -$3.18M | -$2.88M | -$3.28M | -$3.14M | -$3.25M | -$2.69M |
| EPS, basic | -$0.08 | -$0.07 | -$0.08 | - | -$0.07 | -$0.09 | -$0.10 | - | -$0.10 | -$0.10 | -$0.10 | -$0.25 |
| EPS, diluted | -$0.08 | -$0.07 | -$0.08 | - | -$0.07 | -$0.09 | -$0.10 | - | -$0.10 | -$0.10 | -$0.10 | -$0.25 |
| Diluted shares | 34.2M | 33.6M | 33.2M | - | 32.5M | 32.2M | 32.2M | - | 32.1M | 31.9M | 31.4M | - |
Balance sheet
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.40M | $1.48M | $1.55M | $1.24M | $1.50M | $1.91M | $1.05M | $1.27M | $1.23M | $995.0K | $998.0K | $915.0K |
| Short-term investments | $12.47M | $12.21M | $12.65M | $13.93M | $14.53M | $13.69M | $16.20M | $18.65M | $19.52M | $22.24M | $22.80M | $22.93M |
| Receivables | - | $56.0K | - | - | - | - | - | $173.0K | $410.0K | $218.0K | $391.0K | $270.0K |
| Current assets | $14.91M | $14.69M | $15.05M | $15.89M | $17.45M | $16.77M | $18.69M | $21.36M | $22.67M | $24.21M | $25.22M | $25.36M |
| Total assets | $15.07M | $14.87M | $15.23M | $16.08M | $17.65M | $16.98M | $18.91M | $21.59M | $22.91M | $24.36M | $25.37M | $25.52M |
| Current liabilities | $1.75M | $1.50M | $1.24M | $1.97M | $2.07M | $1.89M | $2.00M | $2.50M | $2.00M | $1.68M | $1.66M | $2.03M |
| Total liabilities | $1.87M | $1.64M | $1.39M | $2.13M | $2.24M | $2.07M | $2.19M | $2.70M | $2.22M | $1.77M | $1.77M | $2.15M |
| Shareholders' equity | $14.47M | $13.22M | $13.85M | $15.16M | $15.41M | $14.91M | $16.71M | $18.89M | $20.69M | $22.58M | $23.60M | $23.37M |
Cash flow
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.77M | -$1.74M | -$2.61M | -$1.25M | -$1.51M | -$1.50M | -$2.90M | -$927.0K | -$2.64M | -$1.46M | -$2.31M | -$1.97M |
| Investing cash flow | -$245.0K | $422.0K | $1.23M | $654.0K | -$833.0K | $2.34M | $2.70M | $867.0K | $2.72M | $556.0K | $129.0K | -$593.0K |
| Financing cash flow | $1.94M | $1.25M | $1.69M | $350.0K | $1.93M | $18.0K | -$17.0K | $106.0K | $149.0K | $897.0K | $2.26M | $279.0K |
| Stock-based compensation | $637.0K | $637.0K | $768.0K | $859.0K | $829.0K | $962.0K | $1.03M | $980.0K | $1.09M | $1.24M | $1.11M | $1.16M |
Key ratios
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 8.54 | 9.79 | 12.18 | 8.08 | 8.45 | 8.89 | 9.35 | 8.54 | 11.31 | 14.40 | 15.19 | 12.50 |
Source: XBRL data Anixa Biosciences Inc. files with the SEC, latest filing dated Sep 9, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ANIX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ANIX | - | - | -$10.38M | - | $110.5M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
ANIX FAQ
4 questionsIs ANIX profitable?
No. Anixa Biosciences Inc. reported a net loss of $10.38M for the twelve months ended Jul 31, 2026.How much cash and debt does ANIX have?
Anixa Biosciences Inc. reported $1.40M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did ANIX last report financial results?
The latest statements here come from Anixa Biosciences Inc.'s 10-Q filed on Sep 9, 2026, covering the period ended Jul 31, 2026.Where does this ANIX financial data come from?
Quantisnow builds these statements from the structured XBRL data Anixa Biosciences Inc. files with the SEC. It is provided for information only and is not investment advice.